Cargando…

P805: ALEMTUZUMAB IN RELAPSED SEVERE APLASTIC ANEMIA: LONG-TERM RESULTS OF A PHASE II STUDY

Detalles Bibliográficos
Autores principales:	Aggarwal, N., Manley, A. L., Durrani, J., Shalhoub, R., Rios, O., Lotter, J., Patel, B., Wu, C., Young, N., Groarke, E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431319/ http://dx.doi.org/10.1097/01.HS9.0000846104.45481.e4

Ejemplares similares

S184: SAFETY AND OUTCOMES FOLLOWING IMMUNOSUPPRESSIVE THERAPY WITH ATG/CYCLOSPORIN +/- ELTROMBOPAG FOR OLDER PATIENTS WITH SEVERE APLASTIC ANEMIA
por: Prabahran, Ashvind, et al.
Publicado: (2023)

P832: CLINICAL OUTCOMES AND IMMUNE RESPONSES TO SARS-COV-2 VACCINATION IN PATIENTS WITH SEVERE APLASTIC ANEMIA
por: Rajput, R., et al.
Publicado: (2022)

Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag
por: Zaimoku, Yoshitaka, et al.
Publicado: (2021)

Detectable mutations precede late myeloid neoplasia in aplastic anemia
por: Patel, Bhavisha A., et al.
Publicado: (2020)

Evaluation of efficacy of alemtuzumab in 5 patients with aplastic anemia and/or myelodysplastic neoplasm
por: Füreder, Wolfgang, et al.
Publicado: (2016)

COVID‐19 infection in patients with severe aplastic anaemia
por: Paton, Casey, et al.
Publicado: (2021)

P805: EXTRAMEDULLARY MULTIPLE MYELOMA: MOLECULAR PATHOGENESIS AND NOVEL THERAPEUTIC TARGETS
por: Zihala, David, et al.
Publicado: (2023)

P1310: HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HEPATITIS‑ASSOCIATED APLASTIC ANEMIA AND NON‑HEPATITIS‑ASSOCIATED APLASTIC ANEMIA: A PROPENSITY SCORE-MATCHED ANALYSIS
por: LI, Jia
Publicado: (2023)

P807: APLASTIC ANEMIA FOLLOWING THE SARS-COV-2 VACCINE
por: Babakhanlou, R., et al.
Publicado: (2022)

Autoimmune hemolytic anemia, demyelinating relapse, and AQP1 antibodies after alemtuzumab infusion
por: Tzartos, John S., et al.
Publicado: (2020)

P796: ENRICHED CD16+ MONOCYTES DRIVE T LYMPHOCYTES CELL RESPONSES IN APLASTIC ANEMIA
por: Ge, M., et al.
Publicado: (2022)

P1194: A PHASE IB TRIAL OF ITACITINIB COMBINED WITH ALEMTUZUMAB IN PATIENTS WITH T-CELL PROLYMPHOCYTIC LEUKEMIA (T-PLL)
por: Kadia, T., et al.
Publicado: (2022)

P1335: REPAIR OF DYSFUNCTIONAL BONE MARROW ENDOTHELIAL CELLS ALLEVIATES APLASTIC ANEMIA
por: Tang, Shu-Qian, et al.
Publicado: (2023)

Aplastic Anemia in China
por: Liu, Chunyan, et al.
Publicado: (2018)

P794: EVALUATION OF PEGCETACOPLAN IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS WITH APLASTIC ANEMIA IN THE PRINCE STUDY
por: Bogdanovic, Andrija, et al.
Publicado: (2023)

P763: EFFICACY AND SAFETY OF AVATROMBOPAG IN THE TREATMENT OF TRANSFUSION-DEPENDENT NON-SEVERE APLASTIC ANEMIA
por: Zhang, Ting, et al.
Publicado: (2023)

Efficacy and safety of eltrombopag in Chinese patients with refractory or relapsed severe aplastic anemia
por: Chang, Hong, et al.
Publicado: (2023)

P827: EFFICACY AND SAFETY OF ROMIPLOSTIM ADDED TO IMMUNOSUPPRESSIVE THERAPY AS A FIRST-LINE TREATMENT IN PATIENTS WITH APLASTIC ANEMIA: A PHASE 2/3 CLINICAL TRIAL
por: Yamazaki, H., et al.
Publicado: (2022)

P761: UMBILICAL CORD BLOOD ORIGIN CELLS RECONSTRUCT THE HEMATOPOIESIS OF APLASTIC ANEMIA ANIMAL MODEL
por: Chen, Zesong, et al.
Publicado: (2023)

Immunosuppressive therapy for pediatric aplastic anemia: a North American Pediatric Aplastic Anemia Consortium study
por: Rogers, Zora R., et al.
Publicado: (2019)

P802: PATTERNS OF T-CELL AUTOREACTIVITY DIFFER BETWEEN PEDIATRIC APLASTIC ANEMIA AND HEPATITIS-ASSOCIATED BONE MARROW FAILURE
por: Nováková, M., et al.
Publicado: (2022)

805. Outbreak of Ralstonia pickettii Bacteremia Caused by Contaminated Hydromorphone in a Universitary Hospital in Bogota, Colombia
por: Forero, Shirley Vanessa Correa, et al.
Publicado: (2021)

Aplastic anemia, membranous nephropathy and mercury
por: Rooney, J.
Publicado: (2013)

Idiopathic Aplastic Anemia: An Update
por: Solomou, Elena E.
Publicado: (2019)

Aplastic anemia in the elderly: a nationwide survey on behalf of the French Reference Center for Aplastic Anemia
por: Contejean, Adrien, et al.
Publicado: (2019)

P768: PRELIMINARY EXPLORATION ON LAG-3 EXPRESSION OF BONE MARROW-DERIVED MACROPHAGES IN SEVERE APLASTIC ANEMIA
por: Zhong, Congwei, et al.
Publicado: (2023)

P1353: EXPLORING A NOVEL TREATMENT STRATEGY FOR ACQUIRED APLASTIC ANEMIA TARGETING PPAR SIGNALING PATHWAY.
por: Yang, Liping, et al.
Publicado: (2023)

P792: CLINICAL STUDY OF HETROMBOPAG COMBINED WITH CYCLOSPORINE A IN THE TREATMENT OF CHILDREN WITH NON-SEVERE APLASTIC ANEMIA
por: Chang, Lixian, et al.
Publicado: (2023)

P811: A SINGLE CENTER HISTORICAL CONTROL STUDY OF ELTROMBOPAG ADDED TO IMMUNOSUPPRESSIVE THERAPY FOR SEVERE APLASTIC ANEMIA IN CHILDREN
por: yang, B., et al.
Publicado: (2022)

Aplastic anemia and membranous nephropathy induced by intravenous mercury
por: Priya, N., et al.
Publicado: (2012)

P777: EFFICACY AND SAFETY OF ROMIPLOSTIM COMBINED WITH CYCLOSPORINE A AS A FIRST-LINE TREATMENT IN PATIENTS WITH APLASTIC ANEMIA: A PHASE 2/3 CLINICAL TRIAL.
por: Chiba, Shigeru, et al.
Publicado: (2023)

Alemtuzumab: A new therapy for active relapsing–remitting multiple sclerosis
por: Hartung, Hans-Peter, et al.
Publicado: (2015)

P1308: RUXOLITINIB AS GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN APLASTIC ANEMIA PATIENTS
por: Zhang, Xiaoyu, et al.
Publicado: (2023)

P766: ELTROMBOPAG EFFECTIVELY ALLEVIATES APLASTIC ANEMIA THROUGH REDUCING AKT PROTEIN STABILITY AND MODULATING T LYMPHOCYTE SUBSETS
por: Lin, Zenghua, et al.
Publicado: (2023)

Alemtuzumab: evidence for its potential in relapsing—remitting multiple sclerosis
por: Brown, JWL, et al.
Publicado: (2013)

Management of aplastic anemia during the phase of defervescence of the COVID-19 pandemic()
por: Vallejo Llamas, Juan Carlos
Publicado: (2021)

Fanconi Anemia germline variants as susceptibility factors in aplastic anemia, MDS and AML
por: Przychodzen, Bartlomiej, et al.
Publicado: (2017)

Mixed T Cell Chimerism After Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia Using an Alemtuzumab-Containing Regimen Is Shaped by Persistence of Recipient CD8 T Cells
por: Grimaldi, Francesco, et al.
Publicado: (2017)

P820: PREDICTING RESPONSE TO RABBIT ATG-BASED INTENSIVE IMMUNOSUPPRESSIVE THERAPY COMBINED WITH ELTROMBOPAG IN CHINESE ADULT PATIENTS WITH SEVERE APLASTIC ANEMIA
por: Li, R., et al.
Publicado: (2022)

P803: TELOMERE SHORTENING IN BONE MARROW MESENCHYMAL STEM CELLS OF ACQUIRED APLASTIC ANEMIA PATIENTS ASSOCIATE WITH ALTERED EXPRESSION OF GENES INVOLVED IN TELOMERE MAINTENANCE, DNA DAMAGE, AND SENESCENCE
por: Srivastava, J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_24tbccbcodni9abikcgbq3ej0q